169 related articles for article (PubMed ID: 38237108)
1. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.
Mandarakas MR; Eichinger KJ; Bray P; Cornett KMD; Shy ME; Reilly MM; Ramdharry GM; Scherer SS; Pareyson D; Estilow T; McKay MJ; ; Herrmann DN; Burns J
Neurology; 2024 Feb; 102(3):e207963. PubMed ID: 38237108
[TBL] [Abstract][Full Text] [Related]
2. Reliability of the Charcot-Marie-Tooth functional outcome measure.
Bray P; Cornett KMD; Estilow T; Pareyson D; Zuccarino R; Skorupinska M; Pipis M; Sowden JE; Scherer S; Reilly MM; Shy ME; Herrmann DN; Burns J; Eichinger KJ
J Peripher Nerv Syst; 2020 Sep; 25(3):288-291. PubMed ID: 32844461
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.
Mandarakas MR; Menezes MP; Rose KJ; Shy R; Eichinger K; Foscan M; Estilow T; Kennedy R; Herbert K; Bray P; Refshauge K; Ryan MM; Yiu EM; Farrar M; Sampaio H; Moroni I; Pagliano E; Pareyson D; Yum SW; Herrmann DN; Acsadi G; Shy ME; Burns J; Sanmaneechai O
Brain; 2018 Dec; 141(12):3319-3330. PubMed ID: 30476010
[TBL] [Abstract][Full Text] [Related]
4. The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).
Eichinger K; Burns J; Cornett K; Bacon C; Shepherd ML; Mountain J; Sowden J; Shy R; Shy ME; Herrmann DN
Neurology; 2018 Oct; 91(15):e1381-e1384. PubMed ID: 30232254
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.
Burns J; Ouvrier R; Estilow T; Shy R; Laurá M; Pallant JF; Lek M; Muntoni F; Reilly MM; Pareyson D; Acsadi G; Shy ME; Finkel RS
Ann Neurol; 2012 May; 71(5):642-52. PubMed ID: 22522479
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.
Cornett KM; Menezes MP; Bray P; Halaki M; Shy RR; Yum SW; Estilow T; Moroni I; Foscan M; Pagliano E; Pareyson D; Laurá M; Bhandari T; Muntoni F; Reilly MM; Finkel RS; Sowden J; Eichinger KJ; Herrmann DN; Shy ME; Burns J;
JAMA Neurol; 2016 Jun; 73(6):645-51. PubMed ID: 27043305
[TBL] [Abstract][Full Text] [Related]
7. Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A.
Eichinger K; Sowden JE; Burns J; McDermott MP; Krischer J; Thornton J; Pareyson D; Scherer SS; Shy ME; Reilly MM; Herrmann DN
Front Neurol; 2022; 13():930435. PubMed ID: 35832173
[TBL] [Abstract][Full Text] [Related]
8. Charcot-Marie-Tooth disease and related inherited neuropathies.
Murakami T; Garcia CA; Reiter LT; Lupski JR
Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Italian version of the Charcot-Marie-Tooth Health Index.
Pisciotta C; Ciafaloni E; Zuccarino R; Calabrese D; Saveri P; Fenu S; Tramacere I; Genovese F; Dilek N; Johnson NE; Heatwole C; Herrmann DN; Pareyson D;
J Peripher Nerv Syst; 2020 Sep; 25(3):292-296. PubMed ID: 32511835
[TBL] [Abstract][Full Text] [Related]
10. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
[TBL] [Abstract][Full Text] [Related]
11. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
[TBL] [Abstract][Full Text] [Related]
12. Employment status of patients with Charcot-Marie-Tooth type 1A.
Bjelica B; Brankovic M; Bozovic I; Palibrk A; Kacar A; Rakocevic-Stojanovic V
Acta Neurol Belg; 2022 Jun; 122(3):641-646. PubMed ID: 33491123
[TBL] [Abstract][Full Text] [Related]
13. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
[TBL] [Abstract][Full Text] [Related]
14. Genetic epidemiology of Charcot-Marie-Tooth disease.
Braathen GJ
Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
[TBL] [Abstract][Full Text] [Related]
15. Disease-specific wearable sensor algorithms for profiling activity, gait, and balance in individuals with Charcot-Marie-Tooth disease type 1A.
Dinesh K; White N; Baker L; Sowden JE; Behrens-Spraggins S; Wood E; Charles J; Herrmann DN; Sharma G; Eichinger K
J Peripher Nerv Syst; 2023 Sep; 28(3):368-381. PubMed ID: 37209301
[TBL] [Abstract][Full Text] [Related]
16. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
Mori L; Prada V; Signori A; Pareyson D; Piscosquito G; Padua L; Pazzaglia C; Fabrizi GM; Smania N; Picelli A; Schenone A;
Eur J Phys Rehabil Med; 2019 Feb; 55(1):47-55. PubMed ID: 29898585
[TBL] [Abstract][Full Text] [Related]
17. Atypical presentation of Charcot-Marie-Tooth disease 1A: A case report.
Kulkarni SD; Sayed R; Garg M; Patil VA
Neuromuscul Disord; 2015 Nov; 25(11):916-9. PubMed ID: 26432165
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of the Pediatric Charcot-Marie-Tooth Disease Quality of Life Outcome Measure.
Ramchandren S; Wu TT; Finkel RS; Siskind CE; Feely SME; Burns J; Reilly MM; Estilow T; Shy ME;
Ann Neurol; 2021 Feb; 89(2):369-379. PubMed ID: 33222249
[TBL] [Abstract][Full Text] [Related]
19. Functional outcome measures for infantile Charcot-Marie-Tooth disease: a systematic review.
Mandarakas MR; Rose KJ; Sanmaneechai O; Menezes MP; Refshauge KM; Burns J
J Peripher Nerv Syst; 2018 Jun; 23(2):99-107. PubMed ID: 29521025
[TBL] [Abstract][Full Text] [Related]
20. Novel outcome measures for Charcot-Marie-Tooth disease: validation and reliability of the 6-min walk test and StepWatch(™) Activity Monitor and identification of the walking features related to higher quality of life.
Padua L; Pazzaglia C; Pareyson D; Schenone A; Aiello A; Fabrizi GM; Cavallaro T; Santoro L; Manganelli F; Gemignani F; Vitetta F; Quattrone A; Mazzeo A; Russo M; Vita G;
Eur J Neurol; 2016 Aug; 23(8):1343-50. PubMed ID: 27160471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
